Consensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in B ‐cell acute lymphoblastic leukemia: A report from The Cytometry Society, India
Cytometry Part B: Clinical Cytometry · 04.08.2026
DOI: 10.1002/cyto.b.70055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 04.08.2026. Verfasst von Prashant Tembhare und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology and Cytogenetics, ACTREC, Tata Memorial Center, Homi Bhabha National Institute (HBNI) University, Navi Mumbai, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 119 Literaturangaben.
Abstract (Originalsprache)
Measurable residual disease (MRD) assessment is a key determinant of risk stratification and treatment modification in B‐cell acute lymphoblastic leukemia (B‐ALL). Multicolour flow cytometry (MFC) is a globally adopted rapid and sensitive MRD technique. However, technical practices remain significantly variable across laboratories, compromising assay sensitivity, reproducibility, and comparability. Currently, systemic recommendations providing guidelines on the technical aspects of MFC‐MRD in B‐ALL are unavailable. The Cytometry Society (TCS)‐India undertook a structured consensus process to standardize technical aspects of MFC‐MRD testing. A two‐round Delphi survey was conducted among laboratory professionals and clinicians across India to capture the prevailing practices and priorities. Consensus recommendations were prepared through survey findings and further refined during an in‐person consensus congress with national and international experts from Australia, Egypt, Spain, and Russia. This document provides comprehensive recommendations across pre‐analytic, analytic, and post‐analytic phases of MFC‐MRD including minimal antibody panel, best practices for sample collection, transport, and processing, Instrument setup, quality control, acquisition targets, gating strategies, approaches for LOD/LLOQ definition, hemodilution assessment, etc. A structured MRD report format with quality caveats is also provided. The recommendations are categorized into “Must,” “Preferred,” and “Acceptable” levels to suit diverse resource settings while promoting harmonization. Implementation of these standards will enhance assay sensitivity, reproducibility, and comparability, thereby strengthening MRD‐guided clinical decision‐making in B‐ALL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematopathology and Cytogenetics, ACTREC, Tata Memorial Center, Homi Bhabha National Institute (HBNI) University, Navi Mumbai, India.
- Clinical Division, The Cytometry Society-India, Hyderabad, Telangana, India.
- Neuberg Sehgal Path Lab Private Limited, Mumbai, India.
- Department of Oncopathology, Cancer Institute (W.I.A.), Chennai, India.
- Department of Hematology (Laboratory), SGPGIMS, Lucknow, Uttar Pradesh, India.
- Flow Cytometry Laboratory, Geneflow Labs, Gurugram, India.
ORCID-Profile: Prashant Tembhare, Kunal Sehgal, Karthik Bommannan, Khaliqur Rahman, Man Updesh Singh Sachdeva, Ritu Gupta, Gaurav Chatterjee, Alexander Popov
Zitieren
APA
Tembhare, P., Sehgal, K., Bommannan, K., Rahman, K., Jain, S., Dayal, N., Ghogale, S., Jayaram, A., Sachdeva, M. U. S., Gupta, R., Subramanian, P. G., Manivannan, P., Galande, M., Mundada, M., Rath, A., Datari, P., Rajpal, S., Chatterjee, G., Deshpande, N., …, & Orfao, A. (2026). Consensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in B ‐cell acute lymphoblastic leukemia: A report from The Cytometry Society, India. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.70055
Vancouver
Tembhare P, Sehgal K, Bommannan K, Rahman K, Jain S, Dayal N, et al. Consensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in B ‐cell acute lymphoblastic leukemia: A report from The Cytometry Society, India. Cytometry Part B: Clinical Cytometry. 2026. doi:10.1002/cyto.b.70055
BibTeX
@article{Tembhare2026,
author = {Tembhare, Prashant and Sehgal, Kunal and Bommannan, Karthik and Rahman, Khaliqur and Jain, Sachin and Dayal, Nitin and Ghogale, Sitaram and Jayaram, Ananthvikas and Sachdeva, Man Updesh Singh and Gupta, Ritu and Subramanian, Papagudi G and Manivannan, Prabhu and Galande, Mohan and Mundada, Manasi and Rath, Asish and Datari, Phaneendra and Rajpal, Sweta and Chatterjee, Gaurav and Deshpande, Nilesh and Kathirvel, Kotteeswari and Singh, Kuldeep and Bagal, Bhausaheb and Punatar, Sachin and Pandrowala, Ambreen and Dhamne, Chetan and Handoo, Anil and Julio-Javier and Popov, Alexander and Salem, Dalia and Westerman, David and Orfao, Alberto},
title = {Consensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in B ‐cell acute lymphoblastic leukemia: A report from The Cytometry Society, India},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2026},
doi = {10.1002/cyto.b.70055}
}
EUVIMED